Atrial Fibrillation Ablation and its Impact on Stroke

[1]  G. Bollinger,et al.  Population Study , 2020, Definitions.

[2]  H. May,et al.  Five‐year impact of catheter ablation for atrial fibrillation in patients with a prior history of stroke , 2018, Journal of cardiovascular electrophysiology.

[3]  H. May,et al.  Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long‐term warfarin , 2017, American heart journal.

[4]  N. Gronich,et al.  Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity score-matched analysis. , 2017, Heart rhythm.

[5]  H. May,et al.  Abstract 13877: 5-Year Impact of Catheter Ablation for Atrial Fibrillation in Patients With a Prior History of Stroke , 2016 .

[6]  N. Gronich,et al.  The role of CHADS2 and CHA2DS2‐VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population‐based study , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  L. Friberg,et al.  Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. , 2016, European heart journal.

[8]  R. Mahajan,et al.  Exercise Training and Atrial Fibrillation: Further Evidence for the Importance of Lifestyle Change. , 2016, Circulation.

[9]  E. Dolan,et al.  Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation–Related Stroke: A Population Study , 2015, Stroke.

[10]  Christopher X. Wong,et al.  Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626,603 Individuals in 51 Studies. , 2015, JACC. Clinical electrophysiology.

[11]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[12]  R. Mahajan,et al.  Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. , 2014, Journal of the American College of Cardiology.

[13]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[14]  S. Kalantarian,et al.  Association Between Atrial Fibrillation and Silent Cerebral Infarctions , 2014, Annals of Internal Medicine.

[15]  H. May,et al.  Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. , 2014, Mayo Clinic proceedings.

[16]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[17]  J. Healey,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. , 2014, JAMA.

[18]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[19]  Robert Ryczek,et al.  Cognitive impairment after appropriate implantable cardioverter-defibrillator therapy for ventricular fibrillation. , 2014, Kardiologia polska.

[20]  M. Endres,et al.  Neuropsychological Effects of MRI-Detected Brain Lesions After Left Atrial Catheter Ablation for Atrial Fibrillation: Long-Term Results of the MACPAF Study , 2013, Circulation. Arrhythmia and electrophysiology.

[21]  Atul Verma,et al.  Evaluation and Reduction of Asymptomatic Cerebral Embolism in Ablation of Atrial Fibrillation, But High Prevalence of Chronic Silent Infarction: Results of the Evaluation of Reduction of Asymptomatic Cerebral Embolism Trial , 2013, Circulation. Arrhythmia and electrophysiology.

[22]  T. Chao,et al.  Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[23]  J. Ruskin,et al.  Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. , 2013, Journal of the American College of Cardiology.

[24]  D. Haines,et al.  Microembolism and Catheter Ablation IClinical Perspective , 2013 .

[25]  D. Haines,et al.  Microembolism and Catheter Ablation I: A Comparison of Irrigated Radiofrequency and Multielectrode-phased Radiofrequency Catheter Ablation of Pulmonary Vein Ostia , 2013, Circulation. Arrhythmia and electrophysiology.

[26]  Dhaval Shah,et al.  Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. , 2012, Journal of the American College of Cardiology.

[27]  A. Glanz,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2013, The New England journal of medicine.

[28]  J. Tu,et al.  Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation , 2012, Circulation.

[29]  D. Lake,et al.  Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. , 2012, The American journal of medicine.

[30]  A. Natale,et al.  Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. , 2012, Journal of the American College of Cardiology.

[31]  R. Tilz,et al.  Incidence and Long-Term Follow-Up of Silent Cerebral Lesions After Pulmonary Vein Isolation Using a Remote Robotic Navigation System as Compared With Manual Ablation , 2012, Circulation. Arrhythmia and electrophysiology.

[32]  P. Kirchhof,et al.  Left Atrial Catheter Ablation and Ischemic Stroke , 2012, Stroke.

[33]  B. Gersh.  Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk Factors: The Atherosclerosis Risk in Communities (ARIC) Study , 2012 .

[34]  C. Rowley.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[35]  M. Jhaveri,et al.  One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. , 2011, Clinical therapeutics.

[36]  R. Hunter,et al.  Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death , 2011, Heart.

[37]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[38]  B. Horne,et al.  Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long‐Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation , 2011, Journal of cardiovascular electrophysiology.

[39]  M. Kaps,et al.  Neuropsychological decline after catheter ablation of atrial fibrillation. , 2010, Heart rhythm.

[40]  S. Themistoclakis,et al.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. , 2010, Journal of the American College of Cardiology.

[41]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[42]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[43]  S. Connolly,et al.  Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter , 2009, Circulation.

[44]  H. May,et al.  Warfarin Is Not Needed in Low‐Risk Patients Following Atrial Fibrillation Ablation Procedures , 2009, Journal of cardiovascular electrophysiology.

[45]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[46]  J. Seward,et al.  Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. , 2007, Journal of the American College of Cardiology.

[47]  J. Seward,et al.  Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. , 2006, European heart journal.

[48]  J. Seward,et al.  Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study , 2005, Stroke.

[49]  S. Lydersen,et al.  Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation , 2005, Journal of internal medicine.

[50]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[51]  K. Minematsu,et al.  Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[52]  A. Go.  The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. , 2005, The American journal of geriatric cardiology.

[53]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[54]  C. Israel,et al.  Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. , 2004, Journal of the American College of Cardiology.

[55]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[56]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[57]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[58]  P. Sandercock,et al.  Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial , 2001, Stroke.

[59]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[60]  W. Manning,et al.  When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[61]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[62]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.